Cytovene (ganciclovir) / Roche 
Welcome,         Profile    Billing    Logout  
 268 Diseases   30 Trials   30 Trials   2139 News 


«12...1819202122232425262728...3536»
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
    Review, Journal:  Management of cytomegalovirus corneal endotheliitis. (Pubmed Central) -  Jan 15, 2021   
    There is no consensus on the management of CMV endotheliitis. Further studies are much needed to elucidate the optimal treatment modality, regime, and duration in the treatment and prophylaxis of CMV endotheliitis.
  • ||||||||||  Vistide (cidofovir) / Gilead
    Clinical, Journal:  Cytomegalovirus in Solid Organ Transplant Recipients: Clinical Updates, Challenges and Future Directions. (Pubmed Central) -  Jan 13, 2021   
    Valganciclovir and intravenous ganciclovir remain as drugs of choice for CMV management, and strategies for managing drug-resistant CMV infection are enumerated. There is increasing use of CMV-specific cell-mediated immune assays to stratify the risk of CMV infection after solid organ transplantation, and their potential role in optimizing CMV prevention and treatment efforts is discussed.
  • ||||||||||  grazoprevir (MK-5172) / Merck (MSD), Sunvepra (asunaprevir) / BMS
    Review, Journal:  Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. (Pubmed Central) -  Jan 13, 2021   
    For the majority of these drugs, direct clinical evidence on their efficacy for the treatment of COVID-19 is lacking. Future clinical studies examining these drugs might come to conclude, which can be more useful to inhibit COVID-19 progression.
  • ||||||||||  Vistide (cidofovir) / Gilead, filociclovir (MBX400) / Microbiotix
    Review, Journal:  The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease. (Pubmed Central) -  Jan 13, 2021   
    The most recently approved drug, letermovir (LMV), was approved only for prophylaxis in adult HCMV-seropositive stem cell transplant recipients...Furthermore, FCV was shown to retain activity against a panel of GCV-resistant HCMV isolates, suggesting that it could be a useful alternative therapy for treating patients infected with some GCV-resistant HCMV strains. This review summarizes the early discovery work of FCV and highlights the recent advances in the continued development of this clinical candidate.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Clinical, Journal:  Investigation of Ganciclovir Resistance in Cytomegalovirus Strains Obtained from Immunocompromised Patients (Pubmed Central) -  Jan 9, 2021   
    As a result, the detection of antiviral resistance is important in the follow-up of the patients and guides the clinician in planning of the treatment. It was concluded that the samples that could not be evaluated with the Sanger method should be studied with NGS and further studies are needed to determine the role of the variant sequences detected for the first time in drug resistance.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Preclinical, Journal:  Detection of lentiviral suicide gene therapy in C6 rat glioma using hyperpolarised [1- C]pyruvate. (Pubmed Central) -  Jan 9, 2021   
    In this study, we assessed the pyruvate response to the lentiviral suicide gene therapy of herpes simplex virus-1 thymidine kinase with the prodrug ganciclovir (HSV-TK/GCV) in C6 rat glioma and compared it with traditional MR therapy markers...Hyperpolarised [1- C]pyruvate MRI can offer complementary metabolic information to traditional MR methods to give a more comprehensive picture of the slowly developing gene therapy response. This may benefit the detection of the successful therapy response in patients.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] The diagnostic yield of bone marrow biopsy in patients with liver failure () -  Jan 5, 2021 - Abstract #BSHI2020BSH-I_234;    
    Both patients with hepatosplenic T‐cell lymphoma have died; 1 prior to chemotherapy and 1 patient died with from relapsed disease.  Although we did not diagnose PTLD from the BMB, 8 (8%) patients subsequently received this diagnosis from another biopsy site. Four of the 8 patients have died. In the 4 patients diagnosed with an MPN, all 4 patients (4%) were treated with hydroxycarbamide. The 5 patients who had repeat BMBs were referred for possible HLH of which the diagnosis was subsequently made in 4. Overall, 42 (41%) patients have died. Although the majority of BMBs (75%) did not reveal a diagnosis, a haematological/immunological diagnosis was made in 25% of referrals. Therefore, a BMB remains an important investigation in patients with liver failure and cytopenias with a wide range of potential diagnoses that have implications for therapy.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Journal:  Cell-based interferon gene therapy using proliferation-controllable, interferon-releasing mesenchymal stem cells. (Pubmed Central) -  Jan 2, 2021   
    Moreover, subcutaneous administration of ganciclovir to mice transplanted with NanoLuc luciferase-expressing C3H10T1/2/HSVtk cells for three consecutive days reduced the luminescence signals from the transplanted cells. These results indicate that the cell regulation system using HSVtk gene and ganciclovir can be useful for safe and efficient cell-based IFN-γ gene therapy for cancer.
  • ||||||||||  Foscavir (foscarnet) / Pfizer, Clinigen
    [VIRTUAL] Evaluation of clinical practices of foscarnet at Texas Children's Hospital () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_4619;    
    Patient clinical parameters will be collected and include absolute neutrophil count (ANC) immediately prior to starting foscarnet, the date and value of positive CMV and HHV-6 polymerase chain reaction (PCR) panels from all sources immediately prior to the start of foscarnet, date of second consecutive negative viral PCR result, and date of PCR immediately prior to discontinuation of foscarnet. Operational considerations will be described by presenting foscarnet preparation procedures at TCH.
  • ||||||||||  enoxaparin sodium / Generic mfg.
    [VIRTUAL] Optimizing Clinical Decision Support Tools for Pharmacists () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_1569;    
    Rule that fired multiple times may indicate that they may not be functioning properly. The lengths of time associated with resolving an intervention provided additional dynamics to performance and insight for rule governance.
  • ||||||||||  Foscavir (foscarnet) / Pfizer, Clinigen, Cytovene (ganciclovir) / Roche
    Review, Journal:  Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy. (Pubmed Central) -  Dec 23, 2020   
    Maribavir, an inhibitor of the CMV UL97 kinase, is currently in two phase 3 treatment studies...Vaccine development continues, with several promising candidates currently under study. No longer limited to DNA polymerase inhibitors, the prevention and treatment of CMV infections in the HCT recipient is a rapidly evolving field which should translate into improvements in CMV-related outcomes.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Journal:  Biosynthesis and half-life of MBX-2168-triphosphate in herpes virus-infected cells. (Pubmed Central) -  Dec 18, 2020   
    ACV-TP and MBX-2168-TP also had similar half-lives under these conditions (27.3 ± 4.8 h and 22.2 ± 2.2 h, respectively). We therefore conclude that although MBX-2168 does not follow the classical route of nucleoside analog activation, the metabolic profile of MBX-2168 is similar to other nucleoside analogs such as GCV and ACV that do.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Clinical, Review, Journal:  Orthotopic liver transplantation for Management of a Giant Liver Hemangioma: a case report and review of literature. (Pubmed Central) -  Dec 16, 2020   
    The perspectives of use of the polyR6 carrier produced by oxidative polycondensation as a tool for the development of modular peptide carriers for the purposes of UL gene therapy were discussed. With appropriate patient selection, liver transplantation can be considered as a treatment option for patients with huge HHs which are life-threatening and surgically unresectable.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal, Combination therapy:  Combination Therapy by Tissue-Specific Suicide Gene and Bevacizumab in Intramedullary Spinal Cord Tumor. (Pubmed Central) -  Dec 15, 2020   
    With appropriate patient selection, liver transplantation can be considered as a treatment option for patients with huge HHs which are life-threatening and surgically unresectable. This study suggests that combination therapy using bevacizumab with the pEpo-NI2-SV-TK therapeutic gene could be useful for increasing its therapeutic benefits for intramedullary spinal cord tumors.